Avicena Considers Upping Dose To Clear Way For ALS Indication
This article was originally published in The Pink Sheet Daily
The firm will seek to demonstrate a mortality benefit associated with its creatine-based compound ALS-02.
You may also be interested in...
The Government Accountability Office recommends that Congress establish a bundled payment system for end-stage renal disease services - including Amgen's Epogen (epoetin) - under Medicare Part B "as soon as possible.
A rapid change in Medicare policy on reimbursement for Amgen's Epogen (epoetin alfa) used in dialysis facilities is unlikely, despite impassioned criticism of the current policy from outgoing House Ways and Means Committee Chairman Bill Thomas (R-Calif.)
House Ways and Means Committee Chairman Thomas recommends steps to reduce EPO usage in dialysis facilities during a Dec. 6 hearing.